Effects of STN-DBS on Cognition and Mood in Young-onset Parkinson's Disease: a Two-year Follow-up

Overview

Journal Front Aging Neurosci

Specialty Geriatrics

Date 2024 Jan 31

PMID 38292047

Authors

Jun Hong

Huimin Xie

Yuhua Chen

Di Liu

Tianyu Wang

Kun Xiong

Zhiqi Mao

Affiliations

Soon will be listed here.

Abstract

Background: The effects of subthalamic nucleus deep brain stimulation (STN-DBS) on the cognition and mood of patients with PD are still not uniformly concluded, and young-onset Parkinson's disease (YOPD) is even less explored.

Objective: To observe the effectiveness of STN-DBS on the cognition and mood of YOPD patients.

Methods: A total of 27 subjects, with a mean age at onset of 39.48 ± 6.24 and age at surgery for STN-DBS of 48.44 ± 4.85, were followed up preoperatively and for 2 years postoperatively. Using the Unified Parkinson disease rating scale (UPDRS), H&Y(Hoehn and Yahr stage), 39-Item Parkinson's Disease Questionnaire (PDQ-39), Mini-mental state examination (MMSE), Montreal Cognitive Assessment (MoCA), Hamilton depression scale (HAMD), Hamilton anxiety scale (HAMA) to assess motor, cognition, and mood.

Results: At the 2-year follow-up after STN-DBS, YOPD patients showed significant improvements in motor and quality of life (UPDRS III: < 0.001, PDQ-39: < 0.001); overall cognition was not significantly different from preoperative (MMSE: = 0.275, MoCA: = 0.913), although language function was significantly impaired compared to preoperative (MMSE: = 0.004, MoCA: = 0.009); depression and anxiety symptoms also improved significantly (HAMD: < 0.001, HAMA: < 0.001) and the depression score correlated significantly with motor (preoperative: = 0.493, = 0.009), disease duration (preoperative: = 0.519, = 0.006; postoperative: = 0.406, = 0.036) and H&Y (preoperative: = 0.430, = 0.025; postoperative: = 0.387, = 0.046); total anxiety scores were also significantly correlated with motor (preoperative: = 0.553, = 0.003; postoperative: = 0.444, = 0.020), disease duration (preoperative: = 0.417, = 0.031), PDQ-39 (preoperative: = 0.464, = 0.015) and H&Y (preoperative: = 0.440, = 0.022; postoperative: = 0.526, = 0.005).

Conclusion: STN-DBS is a safe and effective treatment for YOPD. The mood improved significantly, and overall cognition was not impaired, were only verbal fluency decreased but did not affect the improvement in quality of life.

Citing Articles

Association between serum total bilirubin with Parkinson's disease among American adults (NHANES 1999 to 2018).

Su J, Liu L, Wu D, Wang R, Wang Z, Fan E Heliyon. 2024; 10(16):e36053.

PMID: 39224283 PMC: 11366891. DOI: 10.1016/j.heliyon.2024.e36053.

References

Bezdicek O, Mana J, Ruzicka F, Havlik F, Fecikova A, Uhrova T . The Instrumental Activities of Daily Living in Parkinson's Disease Patients Treated by Subthalamic Deep Brain Stimulation. Front Aging Neurosci. 2022; 14:886491. PMC: 9247575. DOI: 10.3389/fnagi.2022.886491. View

Schuepbach W, Rau J, Knudsen K, Volkmann J, Krack P, Timmermann L . Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med. 2013; 368(7):610-22. DOI: 10.1056/NEJMoa1205158. View

Pagano G, Ferrara N, Brooks D, Pavese N . Age at onset and Parkinson disease phenotype. Neurology. 2016; 86(15):1400-1407. PMC: 4831034. DOI: 10.1212/WNL.0000000000002461. View

Mehanna R, Jankovic J . Young-onset Parkinson's disease: Its unique features and their impact on quality of life. Parkinsonism Relat Disord. 2019; 65:39-48. DOI: 10.1016/j.parkreldis.2019.06.001. View

Nasreddine Z, Phillips N, Bedirian V, Charbonneau S, Whitehead V, Collin I . The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005; 53(4):695-9. DOI: 10.1111/j.1532-5415.2005.53221.x. View

Demeter G, Valalik I, Pajkossy P, Szollosi A, Lukacs A, Kemeny F . The effect of deep brain stimulation of the subthalamic nucleus on executive functions: impaired verbal fluency and intact updating, planning and conflict resolution in Parkinson's disease. Neurosci Lett. 2017; 647:72-77. DOI: 10.1016/j.neulet.2017.03.026. View

Folstein M, Folstein S, McHugh P . "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12(3):189-98. DOI: 10.1016/0022-3956(75)90026-6. View

Tomlinson C, Stowe R, Patel S, Rick C, Gray R, Clarke C . Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord. 2010; 25(15):2649-53. DOI: 10.1002/mds.23429. View

Lahtinen M, Haapaniemi T, Kauppinen M, Salokorpi N, Heikkinen E, Katisko J . A comparison of indirect and direct targeted STN DBS in the treatment of Parkinson's disease-surgical method and clinical outcome over 15-year timespan. Acta Neurochir (Wien). 2020; 162(5):1067-1076. PMC: 7156355. DOI: 10.1007/s00701-020-04269-x. View

10.

Levy G . The relationship of Parkinson disease with aging. Arch Neurol. 2007; 64(9):1242-6. DOI: 10.1001/archneur.64.9.1242. View

11.

Tsai S, Hung H, Hsieh T, Lin S, Lin S, Chen S . Long-term outcome of young onset Parkinson's disease after subthalamic stimulation--a cross-sectional study. Clin Neurol Neurosurg. 2013; 115(10):2082-7. DOI: 10.1016/j.clineuro.2013.07.014. View

12.

Aybek S, Gronchi-Perrin A, Berney A, Catalano Chiuve S, Villemure J, Burkhard P . Long-term cognitive profile and incidence of dementia after STN-DBS in Parkinson's disease. Mov Disord. 2007; 22(7):974-81. DOI: 10.1002/mds.21478. View

13.

Pal G, Corcos D, Verhagen Metman L, Israel Z, Bergman H, Arkadir D . Cognitive Effects of Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease with GBA1 Pathogenic Variants. Mov Disord. 2023; 38(12):2155-2162. PMC: 10990226. DOI: 10.1002/mds.29647. View

14.

Santos-Garcia D, De Deus Fonticoba T, Suarez Castro E, Aneiros Diaz A, Cores Bartolome C, Panceiras M . Quality of life and non-motor symptoms in Parkinson's disease patients with subthreshold depression. J Neurol Sci. 2020; 418:117109. DOI: 10.1016/j.jns.2020.117109. View

15.

Seritan A, Spiegel L, Weinstein J, Racine C, Brown E, Volz M . Elevated Mood States in Patients With Parkinson's Disease Treated With Deep Brain Stimulation: Diagnosis and Management Strategies. J Neuropsychiatry Clin Neurosci. 2021; 33(4):314-320. DOI: 10.1176/appi.neuropsych.20080205. View

16.

Asahi T, Nakamichi N, Takaiwa A, Kashiwazaki D, Koh M, Dougu N . Impact of bilateral subthalamic stimulation on motor/cognitive functions in Parkinson's disease. Neurol Med Chir (Tokyo). 2014; 54(7):529-36. PMC: 4533462. DOI: 10.2176/nmc.oa.2013-0364. View

17.

Peto V, Jenkinson C, Fitzpatrick R, Greenhall R . The development and validation of a short measure of functioning and well being for individuals with Parkinson's disease. Qual Life Res. 1995; 4(3):241-8. DOI: 10.1007/BF02260863. View

18.

Etievant A, Lucas G, Dkhissi-Benyahya O, Haddjeri N . The Role of Astroglia in the Antidepressant Action of Deep Brain Stimulation. Front Cell Neurosci. 2016; 9:509. PMC: 4709450. DOI: 10.3389/fncel.2015.00509. View

19.

Carey G, Gormezoglu M, de Jong J, Hofman P, Backes W, Dujardin K . Neuroimaging of Anxiety in Parkinson's Disease: A Systematic Review. Mov Disord. 2020; 36(2):327-339. PMC: 7984351. DOI: 10.1002/mds.28404. View

20.

Castrioto A, Lhommee E, Moro E, Krack P . Mood and behavioural effects of subthalamic stimulation in Parkinson's disease. Lancet Neurol. 2014; 13(3):287-305. DOI: 10.1016/S1474-4422(13)70294-1. View